Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Trillium Therapeutics Inc. (TRIL) since 2021 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Trillium Therapeutics Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1616212.
Total stock buying since 2021: $0.
Total stock sales since 2021: $2,487,278.
Total stock option exercises since 2021: $269,276.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2021 | 0 | $0 | 227,310 | $2,487,278 | 227,310 | $269,276 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2021-07 | 0 | $0 | 3,646 | $32,814 | 3,646 | $1,108 |
| 2021-06 | 0 | $0 | 3,646 | $30,152 | 3,646 | $1,148 |
| 2021-05 | 0 | $0 | 134,146 | $1,235,623 | 134,146 | $49,159 |
| 2021-04 | 0 | $0 | 8,958 | $98,359 | 8,958 | $10,833 |
| 2021-03 | 0 | $0 | 11,875 | $130,633 | 11,875 | $20,692 |
| 2021-02 | 0 | $0 | 12,967 | $165,665 | 12,967 | $31,950 |
| 2021-01 | 0 | $0 | 52,072 | $794,032 | 52,072 | $154,386 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2021-07-07 | Uger Robert (Chief Scientific Officer) | Sale | 3,646 | 9.00 | 32,814 |
| 2021-07-07 | Uger Robert (Chief Scientific Officer) | Option Ex | 3,646 | .30 | 1,108 |
| 2021-06-07 | Uger Robert (Chief Scientific Officer) | Sale | 3,646 | 8.27 | 30,152 |
| 2021-06-07 | Uger Robert (Chief Scientific Officer) | Option Ex | 3,646 | .32 | 1,148 |
| 2021-05-12 | Skvarka Jan (President and CEO) | Sale | 23,802 | 9.24 | 219,882 |
| 2021-05-12 | Skvarka Jan (President and CEO) | Option Ex | 23,802 | .31 | 7,473 |
| 2021-05-11 | Skvarka Jan (President and CEO) | Sale | 106,698 | 9.20 | 981,834 |
| 2021-05-11 | Skvarka Jan (President and CEO) | Option Ex | 106,698 | .38 | 40,545 |
| 2021-05-07 | Uger Robert (Chief Scientific Officer) | Sale | 3,646 | 9.30 | 33,907 |
| 2021-05-07 | Uger Robert (Chief Scientific Officer) | Option Ex | 3,646 | .31 | 1,141 |
| 2021-04-08 | Petrova Penka (Chief Development Officer) | Sale | 5,312 | 11.09 | 58,910 |
| 2021-04-08 | Petrova Penka (Chief Development Officer) | Option Ex | 5,312 | 1.83 | 9,736 |
| 2021-04-07 | Uger Robert (Chief Scientific Officer) | Sale | 3,646 | 10.82 | 39,449 |
| 2021-04-07 | Uger Robert (Chief Scientific Officer) | Option Ex | 3,646 | .30 | 1,097 |
| 2021-03-12 | Uger Robert (Chief Scientific Officer) | Sale | 2,917 | 11.97 | 34,916 |
| 2021-03-12 | Uger Robert (Chief Scientific Officer) | Option Ex | 2,917 | 3.39 | 9,894 |
| 2021-03-10 | Petrova Penka (Chief Development Officer) | Sale | 5,312 | 11.08 | 58,856 |
| 2021-03-10 | Petrova Penka (Chief Development Officer) | Option Ex | 5,312 | 1.83 | 9,705 |
| 2021-03-08 | Uger Robert (Chief Scientific Officer) | Sale | 3,646 | 10.11 | 36,861 |
| 2021-03-08 | Uger Robert (Chief Scientific Officer) | Option Ex | 3,646 | .30 | 1,093 |
| 2021-02-09 | Uger Robert (Chief Scientific Officer) | Sale | 584 | 14.12 | 8,248 |
| 2021-02-09 | Uger Robert (Chief Scientific Officer) | Option Ex | 584 | 9.62 | 5,618 |
| 2021-02-09 | Petrova Penka (Chief Development Officer) | Sale | 508 | 14.17 | 7,200 |
| 2021-02-09 | Petrova Penka (Chief Development Officer) | Option Ex | 508 | 9.62 | 4,887 |
| 2021-02-08 | Uger Robert (Chief Scientific Officer) | Sale | 6,563 | 12.65 | 83,021 |
| 2021-02-08 | Uger Robert (Chief Scientific Officer) | Option Ex | 6,563 | 1.81 | 11,852 |
| 2021-02-08 | Petrova Penka (Chief Development Officer) | Sale | 5,312 | 12.65 | 67,196 |
| 2021-02-08 | Petrova Penka (Chief Development Officer) | Option Ex | 5,312 | 1.81 | 9,593 |
| 2021-01-14 | Skvarka Jan (President and CEO) | Sale | 19,581 | 15.03 | 294,282 |
| 2021-01-14 | Skvarka Jan (President and CEO) | Option Ex | 19,581 | .43 | 8,380 |
| 2021-01-13 | Skvarka Jan (President and CEO) | Sale | 5,419 | 15.04 | 81,507 |
| 2021-01-13 | Skvarka Jan (President and CEO) | Option Ex | 5,419 | .42 | 2,303 |
| 2021-01-11 | Uger Robert (Chief Scientific Officer) | Sale | 584 | 15.20 | 8,878 |
| 2021-01-11 | Uger Robert (Chief Scientific Officer) | Option Ex | 584 | 9.57 | 5,587 |
| 2021-01-11 | Petrova Penka (Chief Development Officer) | Sale | 508 | 15.21 | 7,725 |
| 2021-01-11 | Petrova Penka (Chief Development Officer) | Option Ex | 508 | 9.57 | 4,860 |
| 2021-01-08 | Uger Robert (Chief Scientific Officer) | Sale | 8,517 | 15.66 | 133,384 |
| 2021-01-08 | Uger Robert (Chief Scientific Officer) | Option Ex | 8,517 | 7.17 | 61,066 |
| 2021-01-08 | Petrova Penka (Chief Development Officer) | Sale | 2,604 | 15.50 | 40,364 |
| 2021-01-08 | Petrova Penka (Chief Development Officer) | Option Ex | 2,604 | 3.33 | 8,673 |
| 2021-01-08 | Parsons James T. (Chief Financial Officer) | Sale | 8,505 | 15.79 | 134,268 |
| 2021-01-08 | Parsons James T. (Chief Financial Officer) | Option Ex | 8,505 | 7.25 | 61,618 |
| 2021-01-07 | Uger Robert (Chief Scientific Officer) | Sale | 3,646 | 14.75 | 53,782 |
| 2021-01-07 | Uger Robert (Chief Scientific Officer) | Option Ex | 3,646 | .30 | 1,090 |
| 2021-01-07 | Petrova Penka (Chief Development Officer) | Sale | 2,708 | 14.71 | 39,842 |
| 2021-01-07 | Petrova Penka (Chief Development Officer) | Option Ex | 2,708 | .30 | 809 |
Insider trading activities including stock purchases, stock sales, and option exercises of TRIL listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Trillium Therapeutics Inc. (symbol TRIL, CIK number 1616212) see the Securities and Exchange Commission (SEC) website.